Only one of our models could value this stock with confidence, so use it as a guide.
Not used by alerts or posts.
Valued as a growth company: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
ACCE opinion10x Genomics Inc. Class A Common Stock (TXG)
Fair value (2 models)
Not available
ACCE price target
$60.00
Rating
Not rated
Horizon
12 months
ACCE price target published on 10 Oct 2026, 00:00 CEST.
Price used: $71.55 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, EV/EBITDA comparison, and P/E comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
42
out of 100
Analysts
37% buy
19 covering
1-year return
+435.6%
Dividend yield
0.00%
10x Genomics Inc. Class A Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
10x Genomics sells single-cell and spatial biology instruments, along with the consumables and assays that run on them, to academic and pharma labs. Its moat is a high-gross-margin consumables franchise, with gross margin at 70.1%, that tends to recur once a customer has bought into a platform. The problem is the top line: revenue is shrinking 12.7% year on year and the operating margin is still negative at -15.2%, so the thesis rests on demand stabilising in academic and pharma capital budgets rather than on any current earnings. The 9.4B USD market cap against that backdrop means the market is pricing in a recovery that the reported numbers do not yet show. The score of 42/100 and the forward P/E of 1250x leave little room for error, so this is a name worth a deeper look only if the work points to a clear turn in orders and a path to positive operating margin.